Compare Bristol-Myers Squibb Co (BMY) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs ProShares Ultra QQQ ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.74 (market cap $129.94B), while ProShares Ultra QQQ ETF trades at $92.73. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while ProShares Ultra QQQ ETF pays none. Which is the better fit depends on your goals.
| BMY | QLD | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $65.89 | $100.53 |
52-Week Low | $42.60 | $57.16 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
QLD, the ProShares Ultra QQQ ETF, trades at $92.56, up 1.01% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF, offering 2x daily leverage on the Nasdaq-100, has delivered over 10,000% total return since inception, though it carries amplified risk. Recent institutional buying includes 180 Wealth Advisors increasing its position by 29.4% in Q2 2026, signaling confidence in tech exposure.
The outlook for QLD hinges on tech sector performance, with AI optimism and easing geopolitical tensions as tailwinds. However, leveraged ETF structure risks decay in volatile markets, and a 63.80% historical drawdown underscores volatility. Investors seeking aggressive tech growth may find opportunity, but must tolerate significant swings; diversification and risk management are critical.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
